Pioneering Regenerative Medicine
Without Immunosuppression
Pioneering Regenerative Medicine
Without Immunosuppression
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our lead program iTOL-101 is being developed as a potential cure for Type 1 Diabetes and in a pre-clinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our second lead candidate, iTOL-102, is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Pre-Clinical Non-Human Primate Study Demonstrates Long-Term Success of Allogeneic Islet Implantation Without Chronic Immunosuppression for the Treatment of Diabetes
Data published in peer-reviewed journal, Science AdvancesCo-implantation of allogeneic islets and streptavidin (SA)-FasL-presenting microgels sustained long-term (>6 months) survival of pancreatic islet cells and provided excellent glycemic control in non-human...
iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation Without the Need for Life-Long Immunosuppression
The Company's proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel platform technology, iTOL-100, has demonstrated in animal models of Type 1 Diabetes the ability to induce local immune tolerance and allow long-term engraftment of...
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
iTolerance, Inc. Pre-Clinical Non-Human Primate Study Demonstrates Long-Term Success of Allogeneic Islet Implantation Without Chronic Immunosuppression for the Treatment of Diabetes
Data published in peer-reviewed journal, Science AdvancesCo-implantation of allogeneic islets and streptavidin (SA)-FasL-presenting microgels sustained long-term (>6 months) survival of pancreatic islet cells and provided excellent glycemic control in non-human...
iTolerance, Inc. Closes $17.1 Million Convertible Note Financing to Advance Development of Innovative Regenerative Medicines for Transplantation Without the Need for Life-Long Immunosuppression
The Company's proprietary biotechnology-derived Strepavidin-FasL fusion protein/biotin-PEG microgel platform technology, iTOL-100, has demonstrated in animal models of Type 1 Diabetes the ability to induce local immune tolerance and allow long-term engraftment of...
iTolerance, Inc. to Present at Virtual Investor 2022 Top Picks Conference
Live video webcast presentation on Wednesday, January 26th at 3:00 PM ETMIAMI, FL / January 19, 2022 / iTolerance, Inc. ("iTolerance" or the "Company"), a biotechnology company focused on the development of innovative regenerative medicines, today announced that...